Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Allogene Therapeutics, Inc. (ALLO : NSDQ)

• Company Description    Allogene Therapeutics, Inc. is a clinical-stage immuno-oncology company, primarily focused on the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer.? Number of Employees: 229

• Price / Volume Information    Yesterday's Closing Price: $1.16 Daily Weekly Monthly 20 Day Moving Average: 2,874,493 shares Shares Outstanding: 218.71 (millions) Market Capitalization: $253.70 (millions) Beta: 0.60 52 Week High: $3.78 52 Week Low: $1.09 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -20.00% -24.19% 12 Week -43.14% -38.57% Year To Date -45.54% -43.41%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 210 EAST GRAND AVENUE - SOUTH SAN FRANCISCO,CA 94080 USA ph: 650-457-2700 fax: - ir@allogene.com http://www.allogene.com

• General Corporate Information    Officers David Chang - President; Chief Executive Officer and Member of Arie Belldegrun - Executive Chairman of the Board of Directors Geoffrey Parker - Chief Financial Officer John DeYoung - Director Elizabeth Barrett - Director Peer Information Allogene Therapeutics, Inc. (CORR.) Allogene Therapeutics, Inc. (RSPI) Allogene Therapeutics, Inc. (CGXP) Allogene Therapeutics, Inc. (BGEN) Allogene Therapeutics, Inc. (GTBP) Allogene Therapeutics, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 019770106 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 12/01/24 Next Expected EPS Date: 05/13/25 Share - Related Items Shares Outstanding: 218.71 Most Recent Split Date: (:1) Beta: 0.60 Market Capitalization: $253.70 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.31 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-1.21 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 9.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 05/13/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.58 Price/Cash Flow: - Price / Sales: 1,951.52 EPS Growth vs. Year Ago Period: 34.88% vs. Previous Quarter: -3.70% Sales Growth vs. Year Ago Period: -57.69% vs. Previous Quarter: 4.76% ROE 03/31/25 - - 12/31/24 - -51.95 09/30/24 - -52.13 ROA 03/31/25 - - 12/31/24 - -40.80 09/30/24 - -41.29 Current Ratio 03/31/25 - - 12/31/24 - 8.54 09/30/24 - 9.35 Quick Ratio 03/31/25 - - 12/31/24 - 8.54 09/30/24 - 9.35 Operating Margin 03/31/25 - - 12/31/24 - - 09/30/24 - - Net Margin 03/31/25 - - 12/31/24 - - 09/30/24 - - Pre-Tax Margin 03/31/25 - - 12/31/24 - -1,168,850.00 09/30/24 - -659,137.19 Book Value 03/31/25 - - 12/31/24 - 2.01 09/30/24 - 2.22 Inventory Turnover 03/31/25 - - 12/31/24 - - 09/30/24 - - Debt-to-Equity 03/31/25 - - 12/31/24 - 0.00 09/30/24 - 0.00 Debt-to-Capital 03/31/25 - - 12/31/24 - 0.00 09/30/24 - 0.00

Powered by Zacks Investment Research ©